Clinical trial · Interventional
The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
NCT02704299CI-TRIAL-00021328unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer. | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous T cells-Based Immunotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Autologous T cells-Based Immunotherapy
- description
- Surgery Chemotherapy Autologous T cells-Based Immunotherapy
- interventionNames
- Biological: Autologous T cells-Based Immunotherapy
Primary outcomes (1)
- measure
- Progression-Free-Survival(PFS)
- timeFrame
- 24months
- description
- The primary objective is to assess progression free survival (PFS).
Secondary outcomes (1)
- measure
- Incidences of adverse events or serious adverse events
- timeFrame
- 24months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Aged between 18 to 80 years, males and females. * Subjects who understand and sign the consent form for this study. * The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes. * Subjects are surgical candidates. * No distant metastasis (M0) and No distant lymph node metastasis. * Expected survival time of at least 6 months. Exclusion Criteria: * Subjects who do not sign the consent form for this study. * The subject has an allergic history of medicine or food. * The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system. * The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases. * The subject has an history of other malignant tumour. * The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial. * The subject has participated in any other clinical trial in the 3 months prior to this trial. * The subject is pregnant, lactating or planning to conceive within the next 24 months. * The subject has any other unsuitable or adverse condition to be determined by the investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.